Literature DB >> 17298480

Cardiovascular toxicity due to venlafaxine poisoning in adults: a review of 235 consecutive cases.

C Howell1, A D Wilson, W S Waring.   

Abstract

AIMS: Venlafaxine may increase the risk of arrhythmia in certain patients. We sought to characterize the cardiovascular effects of venlafaxine overdose in adults.
METHODS: A retrospective casenote review of patients admitted to the Royal Infirmary of Edinburgh between January 2000 and June 2006. Haemodynamic and electrocardiographic data were examined in the whole group and a subset that ingested venlafaxine alone.
RESULTS: Two hundred and thirty-five patients (65 men) with median (interquartile range) age 34 years (27-43 years) had ingested venlafaxine 1500 mg (919-2800 mg). Tachycardia (40.0%), high blood pressure (28.4%) and mydriasis (36.6%) were common. Corrected QT >450 ms occurred in seven men (11.1%) and 17 women (10.5%) and transient arrhythmia in three patients. There was a positive correlation between stated quantity of venlafaxine ingested and heart rate [rho = 0.195, 95% confidence interval (CI) 0.054, 0.328] and QTc (rho = 0.314, 95% CI 0.089, 0.509).
CONCLUSIONS: Venlafaxine overdose is associated with sympathomimetic cardiovascular effects and prolonged QTc, irrespective of coingested drugs. These mechanisms might pose an increased risk of arrhythmia and require further exploration.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17298480      PMCID: PMC2000637          DOI: 10.1111/j.1365-2125.2007.02849.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  24 in total

1.  Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data.

Authors:  Nicholas A Buckley; Peter R McManus
Journal:  BMJ       Date:  2002-12-07

2.  Isolated venlafaxine-induced serotonin syndrome.

Authors:  P Kolecki
Journal:  J Emerg Med       Date:  1997 Jul-Aug       Impact factor: 1.484

3.  Hypertensive crisis associated with venlafaxine.

Authors:  Rahul N Khurana; Thomas E Baudendistel
Journal:  Am J Med       Date:  2003-12-01       Impact factor: 4.965

4.  Antidepressant-related deaths and antidepressant prescriptions in England and Wales, 1998-2000.

Authors:  Survjit Cheeta; Fabrizio Schifano; Adenekan Oyefeso; Lucy Webb; A Hamid Ghodse
Journal:  Br J Psychiatry       Date:  2004-01       Impact factor: 9.319

5.  Cardiovascular changes associated with venlafaxine in the treatment of late-life depression.

Authors:  Ellyn M Johnson; Ellen Whyte; Benoit H Mulsant; Bruce G Pollock; Elizabeth Weber; Amy E Begley; Charles F Reynolds
Journal:  Am J Geriatr Psychiatry       Date:  2006-09       Impact factor: 4.105

6.  Mechanism of sodium channel block by venlafaxine in guinea pig ventricular myocytes.

Authors:  M Khalifa; P Daleau; a J Turgeon
Journal:  J Pharmacol Exp Ther       Date:  1999-10       Impact factor: 4.030

7.  Comparative toxicity of citalopram and the newer antidepressants after overdose.

Authors:  C A Kelly; N Dhaun; W J Laing; F E Strachan; A M Good; D N Bateman
Journal:  J Toxicol Clin Toxicol       Date:  2004

8.  Seizures, ventricular tachycardia, and rhabdomyolysis as a result of ingestion of venlafaxine and lamotrigine.

Authors:  C Peano; J B Leikin; P K Hanashiro
Journal:  Ann Emerg Med       Date:  1997-11       Impact factor: 5.721

9.  Quetiapine poisoning: a case series.

Authors:  Corrine R Balit; Geoffrey K Isbister; L Peter Hackett; Ian M Whyte
Journal:  Ann Emerg Med       Date:  2003-12       Impact factor: 5.721

Review 10.  Venlafaxine. A review of its pharmacology and therapeutic potential in depression.

Authors:  S M Holliday; P Benfield
Journal:  Drugs       Date:  1995-02       Impact factor: 9.546

View more
  31 in total

1.  An agenda for research on adverse drug reactions.

Authors:  J K Aronson
Journal:  Br J Clin Pharmacol       Date:  2007-08       Impact factor: 4.335

Review 2.  Medically serious adverse effects of newer antidepressants.

Authors:  Rajnish Mago; Rajeev Mahajan; Michael E Thase
Journal:  Curr Psychiatry Rep       Date:  2008-06       Impact factor: 5.285

3.  Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups.

Authors:  Ragnhild Birkeland Waade; Monica Hermann; Hanne Lewis Moe; Espen Molden
Journal:  Eur J Clin Pharmacol       Date:  2014-05-27       Impact factor: 2.953

Review 4.  Impact of Age and Sex on QT Prolongation in Patients Receiving Psychotropics.

Authors:  Simon W Rabkin
Journal:  Can J Psychiatry       Date:  2015-05       Impact factor: 4.356

Review 5.  Drug induced QT prolongation: the measurement and assessment of the QT interval in clinical practice.

Authors:  Geoffrey K Isbister; Colin B Page
Journal:  Br J Clin Pharmacol       Date:  2013-07       Impact factor: 4.335

6.  Fatal venlafaxine poisonings are associated with a high prevalence of drug interactions.

Authors:  Terhi Launiainen; Ilpo Rasanen; Erkki Vuori; Ilkka Ojanperä
Journal:  Int J Legal Med       Date:  2010-04-30       Impact factor: 2.686

7.  Variability in the quality of overdose advice in Summary of Product Characteristics (SPC) documents: gut decontamination recommendations for CNS drugs.

Authors:  Andrew J B Wall; D N Bateman; W S Waring
Journal:  Br J Clin Pharmacol       Date:  2008-11-17       Impact factor: 4.335

8.  Experience of the use of velaxin (venlafaxine) in anxious depression.

Authors:  N A Il'ina
Journal:  Neurosci Behav Physiol       Date:  2009-03

9.  Effect of selection of QTc formula on eligibility of cancer patients for phase I clinical trials.

Authors:  Mitesh J Borad; Arundhati D Soman; Martin Benjamin; Daniel Casa; Waibhav D Tembe; Barbara F Piper; Ramesh Ramanathan; Raoul Tibes; Gayle Jameson; Karen Ansaldo; Daniel D Von Hoff
Journal:  Invest New Drugs       Date:  2012-12-16       Impact factor: 3.850

10.  Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele.

Authors:  M Hermann; M Hendset; K Fosaas; M Hjerpset; H Refsum
Journal:  Eur J Clin Pharmacol       Date:  2008-01-23       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.